Latest releases

Feb 26, 2020 ı Corporate Releases

Notice of Annual General Meeting

Feb 22, 2020 ı Corporate Releases

FDA approves Lundbeck’s Vyepti™ (eptinezumab-jjmr) – the first and only intravenous preventive treatment for migraine

View all releases

Full year 2019 results

Release

 

Webcast

 

Teleconference slides

 

Annual Report 2019

Read and Download our Annual Report 2019 and Q4 Release

 

Q4 Release

 

 

Read Report 2019

Join Lundbeck

Current open positions

Browse global vacancies

Annual General Meeting

Afgiv fuldmagt eller meld dig til generalforsamlingen

 

Vote by proxy or register for the Annual General Meeting

Share price

Cookie Policy
You have chosen to leave www.lundbeck.com. Lundbeck does not have any responsibility for the content provided by other websites. Click "OK" to continue or "Cancel" to remain on www.lundbeck.com.